England to ban single-use e-cigarettes from June 2025

Oct.24.2024
England to ban single-use e-cigarettes from June 2025
The UK government has announced that England will ban the sale of single-use e-cigarettes from 1 June 2025. On the 22nd of this month, the Welsh Government also issued a statement on its official website confirming a ban on the use of disposable e-cigarettes from June 2025. Currently, two of the four UK regions have issued official statements on the matter.

The UK government announced on its official website on 24th October that England will ban the sale of single-use e-cigarettes from 1 June 2025.

 

Minister for the Circular Economy Mary Creagh confirmed today (24 October) that a new bill has been introduced to Parliament to ban the sale of single-use e-cigarettes from 1 June 2025.

 

The UK government has introduced legislation to ban the sale of remaining stocks by businesses by 1 June 2025, subject to parliamentary approval. Businesses will need to prepare for the ban to take effect. The UK Cabinet Office and local authorities are working closely together to set a consistent date.

 

Between 2012 and 2023, the use of e-cigarettes in England is expected to increase by over 400%, with 9.1% of the UK population currently buying and using these products.

 

Minister for the Circular Economy Mary Creagh said: "Single-use e-cigarettes are extremely wasteful and have caused concern in our towns and cities."

 

"That's why we need to ban single-use e-cigarettes to end the culture of waste in this country," she said. "This is the first step towards a circular economy, where we will extend the use of resources, reduce waste, accelerate progress towards net zero emissions and create thousands of job opportunities across the country."

 

Minister for Public Health and Prevention Andrew Gwynne added: "It is worrying that a quarter of 11-15 year olds used e-cigarettes last year, with disposable e-cigarettes being the choice of most children. Banning disposable e-cigarettes will not only help protect the environment, it will also reduce the appeal of e-cigarettes to children and prevent vulnerable young people from being influenced. The Government will also implement the Tobacco and Electronic Cigarettes Act, the most important public health measure for generations, to protect young people from the effects of nicotine and pave the way for a smoke-free Britain."

 

Green Alliance's Head of Resources, Libby Peake, said: "single-use e-cigarettes are the last thing our children and the planet need, and the unchecked growth of the market for them has gone on for far too long. Each one is a waste of vital resources needed for more sustainable economic development, such as the lithium used in electric vehicle batteries. When littered, the nicotine, plastics and batteries they contain are extremely harmful. Even if thrown away, their batteries can catch fire. Government bans on these harmful devices are a welcome step towards reducing waste in the economy."

 

"The emergence of single-use e-cigarettes, possibly the first mainstream disposable electronic device, is polluting our streets and reflects the continued evolution of the tobacco industry. The UK government's plan to ban these disposable products by 2025 is a popular and important step. The ban not only aims to reduce the number of discarded e-cigarettes, but also challenges the wider trend of disposable technology, which is contributing to a worrying increase in electronic waste, accompanied by fire hazards and the use of scarce materials. From a health perspective, I also welcome this ban and believe it is essential in breaking the control of e-cigarettes over young people and challenging the throwaway culture that threatens to choke our planet," said climate campaigner and environmental scientist, Less Waste Laura.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Retail Case Study | Wisconsin Vape Market One Year After New Regulations: Johnny Vapes Reports 80% Sales Decline as Consumers Shift Online and Across State Lines
Retail Case Study | Wisconsin Vape Market One Year After New Regulations: Johnny Vapes Reports 80% Sales Decline as Consumers Shift Online and Across State Lines
According to WNCY on August 24, 2026, some independent vape retailers in Wisconsin say they have faced significant business pressure one year after new vape regulations took effect. Johnny Vapes, a retailer operating in northeast Wisconsin, said its store count fell from seven locations to four, sales declined by about 80%, and roughly 90% of its inventory was affected. Retailers said some consumers have shifted to online purchases or traveled to neighboring Michigan to buy vape products. The case highlights how local regulations can reshape retail operations, inventory management and consumer purchasing patterns.
Aug.28
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Philip Morris Japan (PMJ) launched the IQOS ILUMA i PRIME Ginza Limited Model Set in Tokyo on September 4, 2026, alongside the opening of IQOS Flagship Ginza, the brand’s first global flagship store. The Oasis Blue edition is limited to 1,814 individually numbered units, with the figure derived from the store’s address at Ginza 1-8-14. The set also includes two Yamanaka-nuri glasses and special packaging, priced at JPY 11,980 and sold exclusively at the Ginza flagship.
Sep.07
Product | RELX Partners With UK E-Liquid Brand T-Juice for Prime Pro × Red Astaire Bundle in France
Product | RELX Partners With UK E-Liquid Brand T-Juice for Prime Pro × Red Astaire Bundle in France
RELX and UK e-liquid brand T-Juice have launched the Prime Pro × Red Astaire bundle in France, combining the RELX Prime Pro open-system pod device with T-Juice’s signature Red Astaire nicotine salt e-liquid. The collaboration retains the existing Prime Pro hardware platform while using an established flavor brand to create a complete open-system offering. The product appeared in French retail and distribution channels in August 2026 and represents a co-branded retail bundle rather than a new device launch.
Aug.27
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
Germany collected €9.789 billion in total tobacco tax revenue from January through August 2026, down 10.8% from a year earlier, according to the Federal Ministry of Finance. Germany's tobacco tax base covers not only cigarettes and fine-cut tobacco but also heated tobacco and vaping liquids taxed as tobacco substitutes. The German Association of the Tobacco Industry and Novel Products, or BVTE, citing federal statistical data, said tax-paid cigarette volume fell 12.6% to 40.6 billion sticks. BVTE is using the latest figures to argue against further tax increases planned from 2027 through 2030, while Germany's parliament is scheduled to hold a first reading of the bill on September 24.
Sep.23
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives